Hologic Inc

Health Care
Medical Electronics
www.hologic.com

Earnings Score
Moat Score
Safety Score

Market Cap $11.98B
PE 22
Debt $2.57B
Cash $1.43B
EV $13.12B
FCF $995.50M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$556.70M
EBIT	$696.80M
ROE	12%
ROA	8%
FCF	$995.50M
Equity	$4.62B
Growth Stability	-63%
PE	21.51
PEG	-1.12
PB	2.59
P/FCF	12.03
P/S	2.97
Price/Cash	0.12
Debt/Equity	0.56
Debt/FCF	2.59
Net Margins	9%
Gross Margins	52%
Op. Margins	17%
Earnings CAGR	4%
Sales Growth YoY	-1%
Sales Growth QoQ	-2%
Sales CAGR	6%
FCF CAGR	10%
Equity CAGR	11%
Earnings Stability	0.04
Earnings Growth YoY	-110%
Earnings Growth QoQ	-109%

Earnings CAGR 5Y	-19%
Sales CAGR 5Y	-4%
FCF CAGR 5Y	-6%
Equity CAGR 5Y	12%
Earnings CAGR 3Y	-7%
Sales CAGR 3Y	-7%
FCF CAGR 3Y	-20%
Equity CAGR 3Y	-2%
Market Cap	$11.98B
Revenue	$4.03B
Assets	$8.55B
Total Debt	$2.57B
Cash	$1.43B
Shares Outstanding	225.77M
EV	13.12B
Earnings Score	6%
Moat Score	89%
Safety Score	61%
Final Score	52%
Working Capital	2.22B
Current Ratio	3.24
Gross Profit	$2.08B
Shares Growth 3y	-4%
Equity Growth QoQ	-3%
Equity Growth YoY	-5%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (64% of total sales, boosted by pandemic), breast health (21% of sales, suppressed by pandemic), surgical (12%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (75%), followed by Europe (16%), Asia (6%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

SEC Filings

Direct access to Hologic Inc (HOLX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 29
2024
- 10-Q Dec 28
- 10-K Sep 28
- 10-Q Jun 29
- 10-Q Mar 30
2023
- 10-Q Dec 30
- 10-K Sep 30
- 10-Q Jul 01
- 10-Q Apr 01

Sector Comparison

How does Hologic Inc compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Hologic Inc compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 4%

Stability 4%

loading chart...

Hologic Inc Discounted Cash Flow

Fully customizable DCF calculator online for Hologic Inc.

Years

Calculation mode

= $20B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$996M	$1.1B	$1.2B	$1.3B	$1.4B	$1.6B	$1.7B	$1.9B	$2.1B	$2.3B	$2.5B	$25B
DCF		$994M	$992M	$990M	$988M	$986M	$984M	$982M	$980M	$979M	$977M	$9.8B
Value	$20B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	09/2015	09/2016	09/2017	09/2018	09/2019	09/2020	09/2021	09/2022	09/2023	09/2024	TTM
Net Margins	5%	12%	25%	-3%	-6%	29%	33%	27%	11%	20%	9%
ROA	-	8%	17%	-3%	-2%	16%	28%	18%	7%	10%	8%
ROE	-	15%	27%	-5%	-10%	41%	44%	27%	9%	15%	12%

Net Margins (9.06%)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	09/2015	09/2016	09/2017	09/2018	09/2019	09/2020	09/2021	09/2022	09/2023	09/2024	TTM
Debt over FCF	-	5.26	-45.05	6.22	6.16	4.54	1.54	1.43	3.45	2.23	2.59
Debt over Equity	1.94	1.7	1.61	1.61	1.57	1.24	0.79	0.58	0.62	0.5	0.56
Growth Stability	-	-	-	-27%	-63%	100%	100%	100%	32%	65%	-63%

Neutral Debt/FCF ratio (2.59)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (0.56)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (-63%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	09/2015	09/2016	09/2017	09/2018	09/2019	09/2020	09/2021	09/2022	09/2023	09/2024	CAGR 5Y
Revenue YoY growth	-	5%	8%	5%	5%	12%	49%	-14%	-17%	-0%	-4%
Earnings YoY growth	-	151%	128%	-115%	83%	-645%	68%	-30%	-65%	73%	-19%
Equity YoY growth	-	3%	30%	-13%	-13%	28%	56%	16%	3%	2%	12%
FCF YoY growth	-	-1%	-114%	-732%	-14%	37%	194%	-8%	-55%	28%	-6%